← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV21행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastaleApproved
Anti-IL12/23 or anti-IL23 - Risankizumab (Anti-IL12/23 or anti-IL23 - Risankizumab)
University of Calgary·Crohn Disease
3 trials
Overview
Program
Anti-IL12/23 or anti-IL23 - Risankizumab
Overview
Company
University of Calgary
Overview
Modality
ANTIBODY
Overview
Target
Crohn Disease
Overview
Indication
Crohn Disease
Overview
Phase
APPROVED
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Established
Overview
Approval status
Approved (flag incomplete)
MoA
Mechanism
with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2
MoA
Biomarker
biomarkers independently predicted survival
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
pd
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.. Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Despite multiple available treatmen…
Clinical
Safety signal
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.. Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Despite multiple available treatmen…
Clinical
Program phase
APPROVED